CSF soluble TREM2 as a measure of immune response along the Alzheimer’s disease continuum
NEUROBIOLOGY OF AGING | OCTOBER 25, 2018
Rauchmann B-S, Schneider-Axmann T, Alexopoulos P and Perneczky R.
Neurobiology of Aging. 2018
This study was peformed using a Simoa® Homebrew assay.
TREM2 was suggested to be an important regulator of microglia during neurodegeneration, but previous studies report conflicting results in relation to soluble TREM2 (sTREM2) in CSF when using clinical criteria to classify Alzheimer’s disease (AD). The present study explores sTREM2 CSF levels and their associations with other biomarkers and cognitive measures in a prospective AD cohort. Based on the available CSF biomarker information, 497 subjects were classified according to the 2018 National-Institute on Aging-Alzheimer’s Association (NIA-AA) research framework guidelines, which group biomarkers into those of amyloid-β deposition, tau pathology and neurodegeneration. CSFs TREM2 concentrations were associated with markers of neurodegeneration and fibrillar tau pathology, but not amyloidosis; sTREM2 concentrations were increased in tTau positive vs negative individuals; sTREM2 was not related to cognitive and other biomarker changes over time; and sTREM2 concentrations increased over time in tTau positive vs negative individuals with AD pathophysiology. The present study provides evidence in support of sTREM2 in CSF as a marker of neuroinflammation across the spectrum of early clinical AD. sTREM2 is linked to neuronal injury and may therefore offer complementary information relevant for diagnostic purposes and novel treatment approaches targeting the immune system in AD.
Share this page